



International Journal of Medical Research & Health Sciences

www.ijmrhs.com

Volume 3 Issue 3

Coden: IJMRHS

Copyright ©2014

ISSN: 2319-5886

Received: 17th Mar 2014

Revised: 15th Apr 2014

Accepted: 22nd Apr 2014

Case report

VENTRICULAR ARRHYTHMIAS IN PATIENTS OF ATRIAL FIBRILLATION TREATED WITH FLECAINIDE: A CASE REPORT

*Barman M¹, Djamel B²

¹Specialist Cardiology, Al Ahli Hospital, Doha, Qatar

²Consultant Interventional Cardiologist, Al Ahli Hospital, Doha, Qatar

*Corresponding author email: drbarman@yahoo.com

ABSTRACT

Purpose: Flecainide is a class 1C antiarrhythmic drug, especially used for the management of supraventricular arrhythmia. Flecainide also has a recognized proarrhythmic effect in all age groups of adult patients treated for ventricular tachycardia. It is used to treat a variety of cardiac arrhythmias including paroxysmal fibrillation, Paroxysmal Supraventricular tachycardia and ventricular tachycardia. Flecainide works by regulating the flow of sodium in the heart, causing prolongation of the cardiac action potential. The proarrhythmic effects however noted are not widely reported. **Case report:** We report a case of paroxysmal atrial fibrillation with structurally normal heart who was treated with oral Flecainide. Despite subjective improvement and no adverse events [QTc prolongation] a repeat holter detected him to have multiple short non sustained ventricular arrhythmias. **Results:** Development of ventricular arrhythmias, salvos & non sustained ventricular tachycardia after a month of initiation of oral Flecainide detected by 24 hours ECG holter lead to discontinuation of Flecainide and subsequent early electro physiological studies and successful ablation. **Conclusion:** Initiation of oral Flecainide in a case of atrial fibrillation with subjective improvement and regular ECG monitoring, no QTc prolongation can still lead to development of dangerous ventricular arrhythmias. A cautious approach and thorough investigations and follow up are recommended.

Key words: Flecainide; Ventricular arrhythmias; Atrial fibrillation.

INTRODUCTION

Atrial fibrillation (AF) is the most common arrhythmia in clinical practice and its prevalence is increasing. Over the last 25 years, flecainide has been used extensively worldwide. Flecainide is a class 1C antiarrhythmic drug used especially for the management of supraventricular arrhythmias like atrial fibrillation (AF)¹ and its capacity to reduce AF symptoms and provide long-term restoration of sinus rhythm (SR) has been well documented.² It causes rate- dependent slowing of the rapid sodium channel slowing phase 0 of depolarization and in high doses inhibits the slow calcium channel.² Flecainide also

slows conduction in all cardiac fibers, increasing conduction times in the atria, ventricles, atrio-ventricular node and His-Purkinje system. Flecainide can also cause myocardial depression. In over- dose cases, flecainide can induce life threatening ventricular arrhythmias and cardiogenic shock³

CASE REPORT

We Report a case seen and managed by Cardiology department, AL Ahli Hospital. Mr. RJN, 44 years male was diagnosed with paroxysmal atrial fibrillation in May 2013 and was under beta blockers and acetyl salicylic acid. He was reviewed in our

hospital in September 2013 because of his disturbing symptoms of palpitations and fatigue. Beta blockers were stopped and he was started with Flecainide (50mg BD) and Dabigatran (110mg BD) with the possibility of electrical cardioversion later if required. Regular follow ups were done and he reported subjective improvement starting after 3 days. Periodic ECG done did not show any QTc prolongation. He was reassessed with holter after one month of Flecainide treatment and found to have multiple short episodes of ventricular arrhythmias [salvos and non-sustained ventricular tachycardia] while still remaining in paroxysms of atrial fibrillation. Thereafter he was admitted to CCU and flecainide was stopped. He was switched back to Beta blockers and again reassessed with holter after a week which showed persistent atrial fibrillation with no ventricular tachyarrhythmia.

Risk Profile: No hypertension or diabetes. Nonsmoker.

Physical examination: 110/70 mm of Hg, PR 102/minute irregular. No evidence of heart failure.

ECG: Initial: Atrial fibrillation, rate ~110/minute. On beta blockers currently.

With Flecainide: Paroxysmal AF with multiple nonsustained ventricular arrhythmias.



Fig 1. Ventricular arrhythmias on holter

ECHO: Atrial fibrillation, Normal LV dimensions and systolic function.

He underwent electrophysiological studies and was successful isolation of all four pulmonary veins for paroxysmal atrial fibrillation with termination of focal site for AF initiation near mid/proximal coronary sinus roof.

DISCUSSION

Pharmacological treatment for atrial fibrillation:

Pharmacological cardioversion of AF can be achieved using a number of drugs with different pharmacological properties, including disopyramide, procainamide, quinidine (all class IA), flecainide, propafenone (both class IC), dofetilide, ibutilide, sotalol, and amiodarone (all class III). Currently, the most commonly used drugs for chemical cardioversion are flecainide, sotalol, and amiodarone. Little difference is observed between the routes of administration for cardioversion rates, although intravenous administration results in faster conversion. Indeed, in patients with recent onset AF, successful cardioversion is reported in 80% of cases with oral therapy, rising only to 90% with intravenous administration¹. Unfortunately, recurrence of AF is common, often requiring long-term drug therapy to improve maintenance of sinus rhythm. For most current antiarrhythmic agents, the relapse rate is at least 50% during the first year²⁻⁵ although slightly better figures are seen with dofetilide⁶ and amiodarone^{7,8}. A number of studies have also demonstrated that flecainide and propafenone are effective drugs for preventing AF recurrence⁹⁻¹¹. The effectiveness of flecainide is comparable to quinidine, but with fewer side effects¹². In contrast, propafenone is more effective for maintenance of sinus rhythm than quinidine. It is as effective as sotalol^{13, 14}. Generally, however, class IC drugs are preferred to class IA drugs in view of their better safety profile^{12, 13}. The success of electrical cardioversion for AF has been quoted as between 75 and 93%, although this depends on left atrial size and co-existing structural heart disease, and ultimately on the duration of AF¹⁵⁻¹⁷. Where there is some concern about a successful restoration of sinus rhythm (for example, previous cardioversion failure or early recurrence of AF), concomitant amiodarone or sotalol can be used pre-cardioversion to improve

the success of electrical cardioversion¹⁸. Such an approach is advocated by the ACC/AHA/ESC guidelines on AF management². The frequency of recurrence of AF after electrical cardioversion is high, and maintenance therapy with antiarrhythmic drugs such as amiodarone or sometimes b-blockers is somewhat useful to prevent AF relapses¹. B-blockers are very effective at controlling ventricular rate and also may reduce the risk of AF recurrence following successful cardioversion (whether spontaneous, pharmacological, or electrical) and are currently used as first-line prophylactic agents in paroxysmal AF. B-blockers have also been shown to reduce the frequency of post-operative AF, although sotalol (which also has class III effects) appears to be the most effective in this setting. As AF commonly coexists with hypertension or congestive heart failure, b-blockers may also be part of conventional therapy in such patients. Rate-limiting, non-dihydropyridine calcium channel blockers (diltiazem, verapamil) are frequently used to optimize rate control where b-blockers are contraindicated or ineffective. An intravenous b-blocker (for example, esmolol or metoprolol) or rate-limiting calcium antagonists (diltiazem, verapamil) are indicated where urgent pharmacological rate control is required. Intravenous amiodarone is a useful alternative in situations where the administration of b-blockers or calcium antagonists is not feasible, such as in the presence of heart failure. All current class IA, IC, and III antiarrhythmic drugs have significant side effects. This includes non-cardiovascular effects (e.g. pulmonary fibrosis and thyroid dysfunction with amiodarone), and of particular importance, the risk of life-threatening ventricular proarrhythmia including TdP in up to 5% of patients^{19, 20}. Most of these antiarrhythmic drugs prevent or terminate AF by altering the function of potassium or sodium channels within the atrial cells. Blockade of potassium channels may prolong ventricular repolarization — and hence, the refractory period — resulting in QT-interval prolongation. Given the risk of severe proarrhythmia, the safety profile of many current antiarrhythmic drugs is far from ideal.

From the early twentieth century, drug therapy has played an important role in the management of atrial arrhythmias. Quinidine was the first antiarrhythmic used to successfully restore and maintain sinus rhythm in atrial fibrillation (AF). Subsequently, a

large number of other drugs have become available. Although the efficacy of many of these agents is impressive, side effects are a frequent occurrence. Amongst the most worrying side effects are QT-interval prolongation and risk of proarrhythmia, including torsade de pointes (TdP)²¹

Flecainide, a class IC anti-arrhythmic agent, depresses the rate of depolarization of cardiac action potentials producing a membrane stabilizing action. It is a very effective anti-arrhythmic agent against supraventricular arrhythmias, nevertheless flecainide is contraindicated in patients with structural heart disease because it increased mortality²². The proarrhythmic effect of flecainide may be related to promoting a reentry in ventricular tissue. The phenomenon is due to a rate-dependent blockade of rapid sodium channels slowing phase 0 of depolarization and an inhibition of the slow calcium channel²³. In cases of overdose, the mortality with class IC agents has been reported to approach 22%. Conduction disturbances began with widening of QRS complex which can rapidly progress to ventricular tachycardia, electromechanical dissociation and asystole leading to cardiac arrest.

Despite the large number of available antiarrhythmic agents, significant QT-interval prolongation and risk of severe proarrhythmia, including torsade de pointes, limit pharmacological opportunities in the management of atrial arrhythmias. The risk of proarrhythmia has been demonstrated in class I and class III drugs, but significant variability has been observed between agents of the same class. Electrophysiological drug effects found to be important in the etiology of proarrhythmia include QT-interval prolongation through selective blockade of the delayed rectifying potassium current (IKr), early afterdepolarizations, transmural dispersion of repolarization, and a reverse rate dependence. Interestingly, less proarrhythmic potential is seen or anticipated with agents that are able to block multiple ion channels and those with atrial selectivity, despite moderate QT prolongation. This observation has helped steer the development of newer drugs, with some promising preliminary results.

CONCLUSION

In conclusion, despite the large number of antiarrhythmic agents that are currently available, modern cardiology is still waiting for the introduction

of new efficient and safe drugs for the treatment of atrial arrhythmias. The ideal anti-arrhythmic agent must efficiently cardiovert AF patients and prevent relapses without proarrhythmic potential. To achieve this, it seems that such drugs should be atrial selective, should have multi ion-channel effects, should not increase transmural dispersion of repolarization, should not produce early after depolarization, and should not exhibit reverse use-dependency.

ACKNOWLEDGEMENT

I would like to thank Aaranya Dev Barman for proof reading, computer typing and internet search on the topic.

Conflict of interest: Nil

REFERENCES

- Hersi A, Wyse DG. Management of atrial fibrillation. *Curr Probl Cardiol* 2005; 30:175–233.
- Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. *Circulation* 2006; 114:e257–e354.
- Courand PY, Sibellas F, Ranc S, Mullier A, Kirkorian G, Bonnefoy E. Arrhythmogenic effect of flecainide toxicity. *Cardiol J*. 2013; 20(2):203-5.
- Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian trial of atrial fibrillation investigators. *N Engl J Med* 2000; 342:913–20.
- Waldo AL. Management of atrial fibrillation: the need for affirmative action. AFFIRM investigators. Atrial fibrillation follow-up investigation of rhythm management. *Am J Cardiol* 1999; 84:698–700.
- Pedersen OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamond) sub study. *Circulation* 2001; 104:2926.
- Affirm. First Antiarrhythmic Drug Sub study Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM sub study of the first antiarrhythmic drug. *J Am CollCardiol* 2003; 42:20–9.
- Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. *N Engl J Med* 2002; 347:1825–33.
- Anderson JL, Gilbert EM, Alpert BL, Henthorn RW, Waldo AL, Bhandari AK et al. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with Trans telephonic monitoring. Flecainide Supraventricular Tachycardia Study Group. *Circulation* 1989; 80:1557–70.
- Pietersen AH, Hellemann H. Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish–Norwegian Flecainide Multicenter Study Group. *Am J Cardiol* 1991; 67:713-17
- A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group. *Circulation* 1995; 92:2550–57.
- Naccarelli GV, Dorian P, Hohnloser SH, Coumel P. Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group. *Am J Cardiol* 1996; 77:53A–59A.
- Lee SH, Chen SA, Chiang CE, Tai CT, Wen ZC, Wang SP et al. Comparisons of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: a double-blind, randomized trial. *J Intern Med* 1996; 239:253–60.

14. Reimold SC, Cantillon CO, Friedman PL, Antman EM. Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. *Am J Cardiol* 1993; 71:558–63
15. Gallagher MM, Guo XH, Poloniecki JD, Guan YY, Ward D, Camm AJ. Initial energy setting, outcome and efficiency in direct current cardioversion of atrial fibrillation and flutter. *J Am CollCardiol* 2001; 38:1498–504.
16. Lundstrom T, Ryden L. Chronic atrial fibrillation. Long-term results of direct current conversion. *Acta Med Scand* 1988; 223:53–59.
17. Dittrich HC, Erickson JS, Schneiderman T, Blacky AR, Savides T, Nicod PH. Echocardiographic and clinical predictors for outcome of elective cardioversion of atrial fibrillation. *Am J Cardiol* 1989; 63:193–7
18. Singh SN, Singh BN, Reda DJ, Fye CL, Ezekowitz MD, Fletcher RD et al. Comparison of sotalol versus amiodarone in maintaining stability of sinus rhythm in patients with atrial fibrillation (Sotalol-Amiodarone Fibrillation Efficacy Trial [Safe-T]). *Am J Cardiol* 2003; 92:468–72
19. Friedman PL, Stevenson WG. Proarrhythmia. *Am J Cardiol* 1998; 82: 50N–58N.
20. Sanguinetti MC, Jurkiewicz NK. Two components of cardiac delayed rectifier K⁺ current. Differential sensitivity to block by class III anti-arrhythmic agents. *J Gen Physiol* 1990; 96:195–215.
21. Eduard Shantsila, Timothy Watson, and Gregory YH Lip, Drug-induced QT-interval prolongation and proarrhythmic risk in the treatment of atrial arrhythmias. *Europace*. 2007; 9 (suppl 4): iv37-iv44
22. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. *N Engl J Med*, 1989; 321: 406–12.
23. Krishnan SC, Antzelevitch C. Flecainide-induced arrhythmia in canine ventricular epicardium. Phase 2 reentry? *Circulation*, 1993; 87: 562–72